PT2292249E - Non-cytotoxic protein conjugates - Google Patents
Non-cytotoxic protein conjugates Download PDFInfo
- Publication number
- PT2292249E PT2292249E PT101841146T PT10184114T PT2292249E PT 2292249 E PT2292249 E PT 2292249E PT 101841146 T PT101841146 T PT 101841146T PT 10184114 T PT10184114 T PT 10184114T PT 2292249 E PT2292249 E PT 2292249E
- Authority
- PT
- Portugal
- Prior art keywords
- protease
- fragment
- sensory afferent
- nociceptive sensory
- site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0426394A GB0426394D0 (en) | 2004-12-01 | 2004-12-01 | Fusion proteins |
GB0504966A GB0504966D0 (en) | 2004-12-01 | 2005-03-10 | Re-targeted toxin conjugates |
GB0504964A GB0504964D0 (en) | 2004-12-01 | 2005-03-10 | Fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2292249E true PT2292249E (en) | 2015-07-13 |
Family
ID=34043886
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT101841500T PT2335718E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
PT101841146T PT2292249E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
PT05810103T PT1830872E (en) | 2004-12-01 | 2005-12-01 | Fusion proteins |
PT58107111T PT1877073E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
PT101665560T PT2366399E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT101841500T PT2335718E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05810103T PT1830872E (en) | 2004-12-01 | 2005-12-01 | Fusion proteins |
PT58107111T PT1877073E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
PT101665560T PT2366399E (en) | 2004-12-01 | 2005-12-01 | Non-cytotoxic protein conjugates |
Country Status (13)
Country | Link |
---|---|
US (5) | US8067200B2 (en) |
EP (4) | EP2366399B1 (en) |
JP (7) | JP5174464B2 (en) |
AT (1) | ATE488245T1 (en) |
CY (2) | CY1111324T1 (en) |
DE (1) | DE602005024857D1 (en) |
DK (6) | DK2335718T3 (en) |
ES (6) | ES2431119T3 (en) |
GB (3) | GB0426394D0 (en) |
HU (2) | HUE025964T2 (en) |
PL (3) | PL2292249T3 (en) |
PT (5) | PT2335718E (en) |
SI (2) | SI1830872T1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
EP2267010B1 (en) * | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Activatable recombinant neurotoxins |
CN100351260C (en) | 2002-11-12 | 2007-11-28 | 布赖汉姆妇女医院 | Polysaccharide vaccine for staphylococcal infections |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7785606B2 (en) * | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
AR060187A1 (en) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | IMMUNOGENIC COMPOSITION |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
AR061669A1 (en) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN |
CN102937653B (en) | 2008-03-14 | 2015-09-09 | 阿勒根公司 | Based on the BoNT/A determination of activity of immunity |
KR101604515B1 (en) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | Immuno-Based Botulinum Toxin Serotype A Activity Assays |
CA2726092A1 (en) | 2008-06-12 | 2009-12-17 | Syntaxin Limited | Suppression of cancers |
US20110171191A1 (en) * | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
ES2660594T3 (en) | 2008-07-21 | 2018-03-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions related to synthetic beta-1,6 glucosamine oligosaccharides |
GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
KR20160103551A (en) | 2008-12-10 | 2016-09-01 | 알러간, 인코포레이티드 | Clostridial toxin pharmaceutical compositions |
ES2440597T3 (en) | 2009-03-13 | 2014-03-07 | Allergan, Inc. | Re-directed endopeptidase activity assays based on immunology |
US8198229B2 (en) * | 2009-05-29 | 2012-06-12 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases |
AU2010353292A1 (en) * | 2009-12-16 | 2012-07-12 | Allergan, Inc. | Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain |
HUE029962T2 (en) | 2010-01-25 | 2017-04-28 | Allergan Inc | Methods of intracellular conversion of single-chain proteins into their di-chain form |
EP2528941A4 (en) * | 2010-01-25 | 2013-05-29 | Univ New York | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
KR101942106B1 (en) | 2010-05-20 | 2019-01-25 | 알러간, 인코포레이티드 | Degradable clostridial toxins |
US20130261062A1 (en) | 2010-10-14 | 2013-10-03 | Allergan, Inc. | Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
WO2012112420A1 (en) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Treatments using psma ligand endopeptidases |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
WO2012174123A1 (en) | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
WO2013009625A1 (en) | 2011-07-08 | 2013-01-17 | Allergan, Inc. | Method for treatment of autonomic nervous system disorders |
KR20140054055A (en) | 2011-07-14 | 2014-05-08 | 알러간, 인코포레이티드 | Methods for treatment of incontinence associated with sexual activity |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
US10451621B2 (en) | 2011-12-31 | 2019-10-22 | Allergan, Inc. | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A |
US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
CN104870468B (en) * | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | Method for producing proteolytically processed polypeptide |
EP2934571B1 (en) | 2012-12-18 | 2018-05-30 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
DK2948174T3 (en) | 2013-01-28 | 2019-12-02 | Univ New York | Methods of treatment using atoxic neurotoxin derivatives |
JP7017932B2 (en) | 2014-12-09 | 2022-02-09 | ニューヨーク・ユニバーシティ | Clostridium neurotoxin fusion proteins, propeptide fusions, their expression and usage |
KR102635959B1 (en) | 2016-09-13 | 2024-02-14 | 알레간 인코포레이티드 | Stabilized non-protein clostridial toxin compositions |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3733093A4 (en) | 2017-12-26 | 2021-07-28 | Goodman Co., Ltd. | Hemostatic device |
US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
WO2019147478A2 (en) * | 2018-01-18 | 2019-08-01 | California Institute Of Technology | Programmable protein circuits in living cells |
DE102018114028A1 (en) * | 2018-06-12 | 2019-12-12 | Bundesrepublik Deutschland (Robert Koch-Institut) | Sample preparation for proteomic examinations |
US11453893B2 (en) | 2018-08-30 | 2022-09-27 | California Institute Of Technology | RNA-based delivery systems with levels of control |
US11542305B2 (en) | 2018-08-31 | 2023-01-03 | California Institute Of Technology | Synthetic protein circuits detecting signal transducer activity |
WO2020146627A1 (en) | 2019-01-10 | 2020-07-16 | California Institute Of Technology | A synthetic system for tunable thresholding of protein signals |
GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
CA2071969A1 (en) * | 1989-12-22 | 1991-06-23 | John R. Murphy | Hybrid molecules having translocation region and cell-binding region |
US5200722A (en) | 1991-11-27 | 1993-04-06 | United Solar Systems Corporation | Microwave window assembly |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
KR960703433A (en) | 1993-06-29 | 1996-08-17 | 로버트 피. 블랙버언 | A TRUNCATED KERATINOCYTE GROWTH FACTOR (KGF) HAVING INCREASED BIOLOGICAL ACTIVITY With Increased Biological Activity |
WO1995032222A1 (en) | 1994-05-19 | 1995-11-30 | Monsanto Company | Method for purifying somatotropin monomers |
GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
EP1241259A1 (en) | 1995-08-15 | 2002-09-18 | Universite Libre De Bruxelles | Peptide having pronociceptive properties |
CA2237296C (en) * | 1995-11-16 | 2008-10-07 | Boehringer Mannheim Gmbh | Process for the preparation of peptides by way of streptavidin fusion proteins |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
WO1999003880A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
ATE227739T1 (en) | 1998-05-13 | 2002-11-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | HYBRID PROTEIN FOR INHIBITING MAST CELL DEGRANULATION AND ITS USE |
DE69934337T2 (en) | 1998-07-22 | 2007-05-24 | Osprey Pharmaceuticals Ltd., Calgary | Conjugates for the treatment of inflammatory diseases and associated tissue damage |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
EP2267010B1 (en) * | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Activatable recombinant neurotoxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
US20080038274A1 (en) * | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
WO2001058936A2 (en) | 1999-12-02 | 2001-08-16 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
MXPA03000014A (en) | 2000-06-28 | 2004-09-13 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals). |
ITMI20022022A1 (en) * | 2002-09-24 | 2004-03-25 | Girolamo Calo' | ANALOGUES OF NOCICETTINA. |
GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
US20040115727A1 (en) | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
WO2006026780A1 (en) | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
US7785606B2 (en) | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059093A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
US8778634B2 (en) * | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
US20080023928A1 (en) * | 2006-07-25 | 2008-01-31 | Lee Cole | Quad roller skate |
AU2008316988A1 (en) * | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
WO2009055351A1 (en) * | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
WO2010085473A1 (en) | 2009-01-20 | 2010-07-29 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
US20100303791A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303789A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases |
US20100303757A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
-
2004
- 2004-12-01 GB GB0426394A patent/GB0426394D0/en not_active Ceased
-
2005
- 2005-03-10 GB GB0504964A patent/GB0504964D0/en not_active Ceased
- 2005-03-10 GB GB0504966A patent/GB0504966D0/en not_active Ceased
- 2005-12-01 PL PL10184114T patent/PL2292249T3/en unknown
- 2005-12-01 PL PL10184150T patent/PL2335718T3/en unknown
- 2005-12-01 EP EP20100166556 patent/EP2366399B1/en active Active
- 2005-12-01 SI SI200531230T patent/SI1830872T1/en unknown
- 2005-12-01 JP JP2007543908A patent/JP5174464B2/en not_active Expired - Fee Related
- 2005-12-01 HU HUE10184114A patent/HUE025964T2/en unknown
- 2005-12-01 US US11/792,210 patent/US8067200B2/en active Active
- 2005-12-01 ES ES05810711T patent/ES2431119T3/en active Active
- 2005-12-01 DK DK10184150.0T patent/DK2335718T3/en active
- 2005-12-01 DK DK05810711T patent/DK1877073T3/en active
- 2005-12-01 EP EP20100157432 patent/EP2204182B1/en active Active
- 2005-12-01 JP JP2007543906A patent/JP5174463B2/en not_active Expired - Fee Related
- 2005-12-01 HU HUE10166556A patent/HUE027025T2/en unknown
- 2005-12-01 PT PT101841500T patent/PT2335718E/en unknown
- 2005-12-01 ES ES10157432T patent/ES2387013T3/en active Active
- 2005-12-01 PT PT101841146T patent/PT2292249E/en unknown
- 2005-12-01 AT AT05810103T patent/ATE488245T1/en active
- 2005-12-01 EP EP10184114.6A patent/EP2292249B1/en active Active
- 2005-12-01 ES ES05810103T patent/ES2356179T3/en active Active
- 2005-12-01 DK DK05810103T patent/DK1830872T3/en active
- 2005-12-01 ES ES10166556.0T patent/ES2540111T3/en active Active
- 2005-12-01 EP EP10184150.0A patent/EP2335718B1/en active Active
- 2005-12-01 DE DE200560024857 patent/DE602005024857D1/en active Active
- 2005-12-01 PT PT05810103T patent/PT1830872E/en unknown
- 2005-12-01 PT PT58107111T patent/PT1877073E/en unknown
- 2005-12-01 PL PL10166556T patent/PL2366399T3/en unknown
- 2005-12-01 DK DK10157432T patent/DK2204182T3/en active
- 2005-12-01 DK DK10184114.6T patent/DK2292249T3/en active
- 2005-12-01 US US11/791,979 patent/US8187834B2/en active Active
- 2005-12-01 SI SI200531796T patent/SI1877073T1/en unknown
- 2005-12-01 DK DK10166556.0T patent/DK2366399T3/en active
- 2005-12-01 ES ES10184150.0T patent/ES2547546T3/en active Active
- 2005-12-01 ES ES10184114.6T patent/ES2548329T3/en active Active
- 2005-12-01 PT PT101665560T patent/PT2366399E/en unknown
-
2007
- 2007-07-27 US US11/829,118 patent/US7658933B2/en active Active
-
2011
- 2011-02-16 CY CY20111100201T patent/CY1111324T1/en unknown
- 2011-03-28 US US13/072,865 patent/US9139635B2/en active Active
- 2011-09-22 US US13/239,573 patent/US8399401B2/en active Active
- 2011-11-25 JP JP2011258137A patent/JP5536017B2/en not_active Expired - Fee Related
-
2012
- 2012-10-25 JP JP2012236094A patent/JP5739854B2/en not_active Expired - Fee Related
-
2013
- 2013-12-20 CY CY20131101153T patent/CY1114954T1/en unknown
-
2014
- 2014-01-29 JP JP2014014941A patent/JP6027035B2/en not_active Expired - Fee Related
-
2016
- 2016-05-18 JP JP2016100002A patent/JP2016147907A/en active Pending
-
2019
- 2019-04-03 JP JP2019071418A patent/JP2019131585A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2292249T3 (en) | Non-cytotoxic protein conjugates | |
WO2006059093A3 (en) | Fusion proteins | |
WO2006059113A3 (en) | Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain | |
WO2007138339A3 (en) | Treatment of pain by use of a single chain polypeptide fusion protein | |
WO2006059105A8 (en) | Non-cytotoxic protein conjugates | |
MX369005B (en) | Fusion proteins and methods for treating, preventing or ameliorating pain. | |
US7452543B2 (en) | Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics | |
EP2316847A3 (en) | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems | |
SI1874932T1 (en) | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein | |
AU2008220715A8 (en) | Plants having enhanced yield-related traits and a method for making the same | |
WO2007138336A3 (en) | Treatment of pain by single chain, polypeptide fusion protein | |
ATE521626T1 (en) | FUSION PROTEIN FOR INHIBITING CERVICAL CANCER | |
MX2012005508A (en) | Plants having enhanced yield-related traits and a method for making the same. | |
AU2011220003A8 (en) | Plants having enhanced yield-related traits and a method for making the same | |
PH12020551876A1 (en) | Nucleic acid for treating mite allergy | |
WO2004053061A3 (en) | Methods of therapy and diagnosis using targeting of cells that express lax | |
WO2008039983A3 (en) | Methods and compositions using mutant gp120 |